Aesica Appoints Bhavesh Kotecha to Newly Created Position of Corporate Services Director

Aesica Appoints Bhavesh Kotecha to Newly Created Position of Corporate Services Director

28 August 2013: Aesica, the global contract development and manufacturing organisation (CDMO), has appointed Bhavesh Kotecha to the new position of Corporate Services Director (CSD). Reporting directly to the CEO of Aesica, Dr. Robert Hardy, Bhavesh will take functional responsibility for delivering operational efficiency and high standards across IT, health and safety, internal audit and M&A processes.

One of the CSD's key responsibilities is the use of IT for further efficiency in the running of M&A processes. The Corporate Services Director with the new team structure will serve as an important asset to the Aesica acquisition strategy, with business integration teams being guided by Bhavesh. The corporate service discipline is a critically important function to meet the transitional challenges that stem from the acquisition process, thereby ensuring the full integration of all functions including finance, HR, sales and marketing, quality control, health and safety regimes, structures and regulatory compliance.

Bhavesh's combined functions input into the management of strategy, cost in line with pre-set budgets, new technologies and ERP systems. Aesica has established an integrated team structure to assist the CSD with his multiple responsibilities and the effective implementation of best practice programmes and quality control across his functional competencies within the company. He is supported in his role by three IT country managers, a global health and safety manager and specialist technical architect.

Commenting on the Corporate Services Director's role, Dr. Robert Hardy, Aesica CEO said: "The CSD position and responsibilities are crucial to the Aesica strategy and will be central to maximising efficiency and operational performance, ensuring compliance with the highest standards of health and safety, whilst achieving the optimum integration of personnel, corporate infrastructure, technology and processes as we continue to make strategic acquisitions".

About Aesica:

Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world's leading pharmaceutical companies and emerging biotechnology organisations.

The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.

- Aesica is one of the UK's fastest growing companies and over the last five years has more than trebled its turnover.

- The company currently employs approximately 1,300 people.

- In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy. It also has sales representation in San Diego and Shanghai.

- The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: +44 (0) 20 7203 6740 or e-mail; [email protected]

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.